Difference between revisions of "Team:SDU-Denmark/Proof"

Line 19: Line 19:
 
<h5>Purified bacteriocins inhibit the growth of <i>MRSA</i> and <i>P. aeruginosa</i></h5>
 
<h5>Purified bacteriocins inhibit the growth of <i>MRSA</i> and <i>P. aeruginosa</i></h5>
 
<p> Our MIC test shows <a href="https://2016.igem.org/Team:SDU-Denmark/Demonstrate#MIC" target="_blank">growth inhibition</a> of the strains MRSA:USA300, MRSA:CC398, hetero-VISA and <i>P. aeruginosa</i>:PAO1. The bacteriocins LacticinQ and the hybrid Laterosporulin-ThuricinS did not elicit their activity towards <em>P. aeruginosa.</em> However, the absence of inhibition could be due to a higher MIC value, i.e. the need of a higher concentration to inhibit growth than used in the MIC test, which still leaves the hybrid as a potential inhibitor of <i>P. aeruginosa.</i></p>
 
<p> Our MIC test shows <a href="https://2016.igem.org/Team:SDU-Denmark/Demonstrate#MIC" target="_blank">growth inhibition</a> of the strains MRSA:USA300, MRSA:CC398, hetero-VISA and <i>P. aeruginosa</i>:PAO1. The bacteriocins LacticinQ and the hybrid Laterosporulin-ThuricinS did not elicit their activity towards <em>P. aeruginosa.</em> However, the absence of inhibition could be due to a higher MIC value, i.e. the need of a higher concentration to inhibit growth than used in the MIC test, which still leaves the hybrid as a potential inhibitor of <i>P. aeruginosa.</i></p>
 +
 
<h5>Synergistic effect of bacteriocins</h5>
 
<h5>Synergistic effect of bacteriocins</h5>
 
<div>
 
<div>
Line 27: Line 28:
  
 
<div id="demonstrate4" class="modalDialog" style="overflow: auto;max-height: 100vh;">
 
<div id="demonstrate4" class="modalDialog" style="overflow: auto;max-height: 100vh;">
−
<div>
+
  <div>
−
<a href="#close" title="Close" class="close">X</a>
+
      <a href="#close" title="Close" class="close">X</a>
−
<img src="https://static.igem.org/mediawiki/2016/e/eb/T--SDU-Denmark--MICvisualdatacorrect.png" alt="" width="100%">
+
      <img src="https://static.igem.org/mediawiki/2016/e/eb/T--SDU-Denmark--MICvisualdatacorrect.png" alt="" width="100%">
−
<p>Figure 4 visualizes MIC values for each bacteriocin towards each tested strain. The respective strains are listed in the x-axis and the MIC values are plotted logarithmic(2) on the y-axis. The lowest bar indicates the bacteriocin eliciting the strongest effect.</p>
+
      <p>Figure 4 visualizes MIC values for each bacteriocin towards each tested strain. The respective strains are listed in the x-axis and the MIC values are plotted logarithmic(2) on the y-axis. The lowest bar indicates the bacteriocin eliciting the strongest effect.</p>
−
</div>
+
    </div>
 
</div>
 
</div>
 +
 +
<p  class="figuretext"><em>Figure 2: The graphs shows the results of MIC tests performed on cell lysates containing respective bacteriocins. The graphs are plotted as OD/hours where SN = Supernatant. The color code indicates the concentrations used [µg/mL]. SDU11 = ThuricinS <a href="http://parts.igem.org/Part:BBa_K2018011" target="_blank">K2018011</a> tested on E. Cloacae, SDU14 = Laterusporulin-ThuricinS <a href="http://parts.igem.org/Part:BBa_K2018014" target="_blank">K2018014</a> tested on P. aeruginosa.</em></p></div>
 +
 
<p>Compared to traditional antibiotics, our results show that the bacteriocins has <a href="https://2016.igem.org/Team:SDU-Denmark/Demonstrate#synergy" target="_blank">similar or better effect</a>. The bacteriocins show inhibition of growth towards MRSA strains and <em>P. aeruginosa</em> at concentrations were the traditional antibiotics does not elicit an effect. The bacteriocins therefore show promising results to support the idea of bacteriocins being a supplement for traditional antibiotics, of which multiresistant bacterias has become less sensitive towards.</p>
 
<p>Compared to traditional antibiotics, our results show that the bacteriocins has <a href="https://2016.igem.org/Team:SDU-Denmark/Demonstrate#synergy" target="_blank">similar or better effect</a>. The bacteriocins show inhibition of growth towards MRSA strains and <em>P. aeruginosa</em> at concentrations were the traditional antibiotics does not elicit an effect. The bacteriocins therefore show promising results to support the idea of bacteriocins being a supplement for traditional antibiotics, of which multiresistant bacterias has become less sensitive towards.</p>
 
<p>The bacteriocins not only inhibited the growth of the tested strains BUT the bacteriocins also showed <a href="https://2016.igem.org/Team:SDU-Denmark/Demonstrate#synergy" target="_blank">synergestic effect</a>. The synergistic effect is shown by a decrease in MIC when the bacteriocin Laterosporulin and ThuricinS are combined as a hybrid compared to their MIC value as single proteins. The hybrid LacticinQ-LacticinZ also shows a decreased MIC compared to LacticinQ as a single acting bacteriocin. The absence of inhibition towards<i> P. aeruginosa </i> by Laterosporulin-ThuricinS when in a hybrid, compared to their single protein effect, could be stated as a loss of effect. However, the MIC values overall decrease towards the<i> S. aureus</i> strains, thus indicating a stronger effect. The observation leaves the possibility of a gain of effect towards strains not tested in the MIC test. The gain of effect could possible prove another characteristic of the designed hybrid bacteriocins. This leaves the opportunity to design an antimicrobial compound as needed.</p></div>
 
<p>The bacteriocins not only inhibited the growth of the tested strains BUT the bacteriocins also showed <a href="https://2016.igem.org/Team:SDU-Denmark/Demonstrate#synergy" target="_blank">synergestic effect</a>. The synergistic effect is shown by a decrease in MIC when the bacteriocin Laterosporulin and ThuricinS are combined as a hybrid compared to their MIC value as single proteins. The hybrid LacticinQ-LacticinZ also shows a decreased MIC compared to LacticinQ as a single acting bacteriocin. The absence of inhibition towards<i> P. aeruginosa </i> by Laterosporulin-ThuricinS when in a hybrid, compared to their single protein effect, could be stated as a loss of effect. However, the MIC values overall decrease towards the<i> S. aureus</i> strains, thus indicating a stronger effect. The observation leaves the possibility of a gain of effect towards strains not tested in the MIC test. The gain of effect could possible prove another characteristic of the designed hybrid bacteriocins. This leaves the opportunity to design an antimicrobial compound as needed.</p></div>

Revision as of 12:51, 19 October 2016

Proof of Concept

Bacteriocins - They work!

During the project we designed BioBricks, which contain the genes encoding a single bacteriocin or a hybrid bacteriocin. We purified the bacteriocins using the IMPACT method and determined the respective concentrations using a Bradford Standard Protein Assay with Bovine Serum Albumin (BSA). The first key criteria in order to purify the bacteriocins were to correctly incorporate the bacteriocin into the IMPACT vector pTXB1. We identified successful ligation between our bacteriocins and the pTXB1 with colony PCR, thus the first key criteria were achieved. Let the purification begin!

Purified bacteriocins inhibit the growth of MRSA and P. aeruginosa

Our MIC test shows growth inhibition of the strains MRSA:USA300, MRSA:CC398, hetero-VISA and P. aeruginosa:PAO1. The bacteriocins LacticinQ and the hybrid Laterosporulin-ThuricinS did not elicit their activity towards P. aeruginosa. However, the absence of inhibition could be due to a higher MIC value, i.e. the need of a higher concentration to inhibit growth than used in the MIC test, which still leaves the hybrid as a potential inhibitor of P. aeruginosa.

Synergistic effect of bacteriocins
X

Figure 4 visualizes MIC values for each bacteriocin towards each tested strain. The respective strains are listed in the x-axis and the MIC values are plotted logarithmic(2) on the y-axis. The lowest bar indicates the bacteriocin eliciting the strongest effect.

Figure 2: The graphs shows the results of MIC tests performed on cell lysates containing respective bacteriocins. The graphs are plotted as OD/hours where SN = Supernatant. The color code indicates the concentrations used [µg/mL]. SDU11 = ThuricinS K2018011 tested on E. Cloacae, SDU14 = Laterusporulin-ThuricinS K2018014 tested on P. aeruginosa.

Compared to traditional antibiotics, our results show that the bacteriocins has similar or better effect. The bacteriocins show inhibition of growth towards MRSA strains and P. aeruginosa at concentrations were the traditional antibiotics does not elicit an effect. The bacteriocins therefore show promising results to support the idea of bacteriocins being a supplement for traditional antibiotics, of which multiresistant bacterias has become less sensitive towards.

The bacteriocins not only inhibited the growth of the tested strains BUT the bacteriocins also showed synergestic effect. The synergistic effect is shown by a decrease in MIC when the bacteriocin Laterosporulin and ThuricinS are combined as a hybrid compared to their MIC value as single proteins. The hybrid LacticinQ-LacticinZ also shows a decreased MIC compared to LacticinQ as a single acting bacteriocin. The absence of inhibition towards P. aeruginosa by Laterosporulin-ThuricinS when in a hybrid, compared to their single protein effect, could be stated as a loss of effect. However, the MIC values overall decrease towards the S. aureus strains, thus indicating a stronger effect. The observation leaves the possibility of a gain of effect towards strains not tested in the MIC test. The gain of effect could possible prove another characteristic of the designed hybrid bacteriocins. This leaves the opportunity to design an antimicrobial compound as needed.